Monil Shah, PharmD, MBA, is the Chief Development Officer for WindMIL Therapeutics and has over 20 years of pharmaceutical and biotechnology industry experience in oncology drug development. Prior to joining WindMIL, Dr. Shah was the Chief Operating Officer of IRX Therapeutics/Brooklyn ImmunoTherapeutics. Prior to that, he was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah was Head of Clinical Development and Operations at Ventrus Biosciences prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and led the clinical portfolio and strategic planning function at Celgene Corporation. He led the Oncology Development and Operations activities at Fibrogen and Novacea. Dr. Shah began his career at Novartis in the Oncology Early Development Group leading clinical trials prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers University in New Jersey and his MBA from Florida Institute of Technology.
Dr. Shah leads the Clinical Development group at WindMIL Therapeutics, providing strategic direction to clinical development planning and ensuring effective and efficient execution. He uses his extensive clinical, scientific, medical, regulatory, and operational experience in the biotechnology/pharmaceutical industry to manage the company’s clinical development, regulatory, medical, statistics, data management, and clinical operations functions while supporting scientific, manufacturing, investor, and business and corporate development activities.